2017
DOI: 10.1111/joms.12217
|View full text |Cite
|
Sign up to set email alerts
|

Flow Signals: Evidence from Patent and Alliance Portfolios in the US Biopharmaceutical Industry

Abstract: Integrating signaling theory and the portfolio diversity literature, we theorize that diversity in a firm's patent and alliance portfolios sends contrasting flow signals impacting its market value in a nuanced way. Diversity in an alliance portfolio mediates the patent portfolio diversity -market value relationship by suppressing the negative effect of patent portfolio diversity creating an overall positive effect. We test our mediation model on a longitudinal set of 225 U.S. biopharmaceutical firms that were … Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1
1
1

Citation Types

0
44
0

Year Published

2017
2017
2023
2023

Publication Types

Select...
8

Relationship

0
8

Authors

Journals

citations
Cited by 51 publications
(44 citation statements)
references
References 135 publications
0
44
0
Order By: Relevance
“…Since I-U-R alliances typically often last for 5 years and termination dates are rarely reported, we follow previous research in applying a 5-year window to construct a focal firm's I-U-R alliance portfolio [20,50]. For example, the I-U-R alliance portfolio of year t is computed as the collection of I-U-R alliances established from the year t-5 to the year t-1.…”
Section: Samplementioning
confidence: 99%
“…Since I-U-R alliances typically often last for 5 years and termination dates are rarely reported, we follow previous research in applying a 5-year window to construct a focal firm's I-U-R alliance portfolio [20,50]. For example, the I-U-R alliance portfolio of year t is computed as the collection of I-U-R alliances established from the year t-5 to the year t-1.…”
Section: Samplementioning
confidence: 99%
“…For example, in our case, it might be possible that as soon as firms have more patents, they are more attractive as alliance partners. Prior research suggests that in technology‐intensive industries, such as biotechnology, a new patent is not only a revenue‐generating invention but also a signal of the firm's underlying technological capabilities, important for potential future alliance partners (Caner et al, ; Stuart et al, ). To address this issues, we used the information from our secondary longitudinal dataset on the complete population of German biotech firms from 1996 until 2012 (see Oehme and Bort () for details).…”
Section: Resultsmentioning
confidence: 99%
“…Finally, the dependent variable firm innovation is based on a three‐year window from 2014 to 2016. In doing so, we made sure that we control the fact that the innovation performance of a firm can also serve as a signal for the attractiveness of the firm as potential alliance partner which increases the chance to find and form new partnerships (e.g., Stuart, ; Caner et al, ; Stuart et al, ).…”
Section: Methodsmentioning
confidence: 99%
See 1 more Smart Citation
“…Second, even if the information is accurate, it is not always perfectly correlated with the unobserved construct it is supposed to capture (Busenitz et al, 2005;Connelly et al, 2011). Nonetheless, in the absence of more reliable insights, signals are useful cues that shed at least some light on matters that investors find hard to gauge otherwise (Caner et al, 2018;Schepker et al, 2018). Investors have for instance been shown to use managers' compensation structures, acquisition experience, and cultural backgrounds as signals of managers' motives for making acquisitions (Haleblian et al, 2009;Schijven and Hitt, 2012).…”
Section: Information Asymmetries and Signalsmentioning
confidence: 99%